Prediction Case File
YouTubeEvaluation Complete

Friends! In this video, I'm going to talk about the best quality stocks to consider

2 extracted signals · 2 resolved · 0 still active

The Patient Investor profile imageThe Patient Investor10 Sept 2025, 22:14 UTC
Video preview for Friends! In this video, I'm going to talk about the best quality stocks to consider
Signals
2
Eligible signals in this source
Open
0
Still being tracked
Resolved
2
Evaluable outcomes
Successful
0
Canonical correct result
Failed
2
Canonical failed result
Resolved success
0%
Open and excluded signals omitted
Source overview

AI-generated source summary

This is a fundamental analysis of two stock CPRT and UBER. The first stock, Copart, is currently priced at $48.07, down -14.65% year to date. He states he is looking for a target price of $59 and owns call options going into 2027. He explains that Copart makes revenue in two ways, service revenue which is currently up 7.1% and vehicle sales. Next is UBER, which is showing a strong YTD returns, this is a very disliked stock. Price of the stock is $94.36 with a target price of around $110, for a stock that the market underappreciates. Uber's moat and also annual earnings per share growth, of 30% or greater. Analyst are showing that earnings will continue to grow as this will impact the share price. Looking at delivery segment gross bookings are up 20% in 2025.

AI-generated summary based on the source content.

Case timeline

Evidence and evaluation progress

  1. Original source published

    The analyst published the original source item.

  2. First prediction resolved

    The first evaluable outcome in this case reached a terminal result.

  3. Case evaluation completed

    All evaluable predictions in this case reached terminal outcomes.

  4. Source recorded by Tahlil Plus

    The public source was preserved as the evidence record for this case.

  5. Market predictions extracted

    2 eligible signals linked to this case.

  6. Outcome tracking started

    Tahlil Plus began monitoring the extracted predictions.

Extracted intelligence

Signals in this source

Continue the evidence trail
Analyst history

The Patient Investor

Tracked signals
292
Historical success
32.9%
Methodology & disclosure

Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.